Oncolytics Biotech Wins FDA Fast Track for Pelareorep
SAN DIEGO, July 20, 2026 Oncolytics Biotech announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
Oncolytics Biotech
Advertisement
Oncolytics Advances REO 033 Development
SAN DIEGO, July 13, 2026 Oncolytics Biotech announced a significant clinical and regulatory update for its REO 033 randomized...
Oncolytics Reports Promising Pelareorep Data in RAS Cancers
SAN DIEGO, California, USA, June 1, 2026 Oncolytics Biotech has announced encouraging preclinical findings for pelareorep in combination with...
Oncolytics’ Pelareorep Shows Strong KRAS-Targeted Immune Activation at ASCO 2026
SAN DIEGO, May 22, 2026 Oncolytics Biotech® announced new translational data from its GOBLET and AWARE-1 studies showing that...
Oncolytics Biotech Reports Strong mCRC Response Data
SAN DIEGO, May 04, 2026 Oncolytics Biotech® Inc. has reported compelling durability data from its REO 022 study, highlighting...
Advertisements
Oncolytics Advances Pelareorep Toward Anal Cancer Approval
San Diego, California, USA, April 6, 2026 FDA Engagement Signals Registrational Pathway Progress In a key development for oncolytic...
Oncolytics Biotech Forms GI Tumor Board to Advance Pelareorep
CALGARY, Alberta, November 4, 2025 — Oncolytics Biotech® Inc. (NASDAQ: ONCY; TSX: ONC) announced the formation of a Gastrointestinal...
Oncolytics Prepares Registration Trial in First-Line Pancreatic Cancer
SAN DIEGO, Sept. 29, 2025 — Oncolytics Biotech® Inc. (NASDAQ: ONCY) today announced a key update on its plan...
Oncolytics Biotech Shows Favorable Safety for Pelareorep in GI Tumors
SAN DIEGO, Sept. 2, 2025 – Oncolytics Biotech® Inc. (Nasdaq: ONCY), a clinical-stage immunotherapy company, announced updated clinical safety...
Advertisement
